Tuberculosis (TB) still represents an important issue for public health in underdeveloped
countries, but the use of antitumor necrosis factor agents (anti‐TNF) for the treatment of …

The ability of Mycobacterium tuberculosis to cause disease hinges upon successfully
thwarting the innate defenses of the macrophage host cell. The pathogen's trump card is its …

Reductive evolution has endowed Mycobacterium tuberculosis (M. tb) with moonlighting in
protein functions. We demonstrate that RipA (Rv1477), a peptidoglycan hydrolase, activates …

Mycobacterium tuberculosis (Mtb) is known to evade host immune responses and persist in
macrophages for long periods. A mechanism that the host uses to combat Mtb is xenophagy …

The antituberculosis (anti-TB) drug rifampin (RIF) binds to the beta subunit of the RNA
polymerase (RpoB) of Mycobacterium tuberculosis, but the bactericidal responses triggered …

Bacillus Calmette–Guérin (BCG) immunotherapy for bladder cancer has been used since
1976 when the first evidence of its ability to lower recurrence and progression rates was …

Tuberculosis (TB) is currently the second deadliest infectious disease. Existing
antitubercular therapies are long, complex, and have severe side effects that result in low …

Tuberculosis (TB) is still the principal cause of death caused by a single infectious agent,
and the balance between the bacillus and host defense mechanisms reflects the different …

Protective immunity against Mycobacterium tuberculosis (Mtb) requires IFNG. Besides, IFNG-
mediated induction of autophagy suppresses survival of virulent Mtb in macrophage cell …

The convergence between tuberculosis (TB) and diabetes mellitus (DM) will represent a
major public health challenge in the near future. DM increases the risk of developing TB by …